NEXT BIOMETRICS GROUP ASA |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.52 NOK | +0.24% |
|
-2.07% | +20.00% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 544.1 | 154.6 | 197.8 | 723.4 | 413.5 | 738.6 |
| Enterprise Value (EV) 1 | 497.8 | 73.84 | 141.1 | 624.3 | 346.2 | 672.4 |
| P/E ratio | -3.01 x | -0.89 x | -1.64 x | -11.7 x | -8.91 x | -10.3 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 5.02 x | 1.83 x | 3.42 x | 14.3 x | 8.56 x | 21.5 x |
| EV / Revenue | 4.59 x | 0.87 x | 2.44 x | 12.3 x | 7.17 x | 19.6 x |
| EV / EBITDA | -3.09 x | -0.48 x | -1.62 x | -11.8 x | -8.1 x | -11.2 x |
| EV / FCF | -6.09 x | -1.09 x | -2.89 x | -33.6 x | -20.1 x | -19.7 x |
| FCF Yield | -16.4% | -91.8% | -34.6% | -2.98% | -4.99% | -5.08% |
| Price to Book | 4.56 x | 1.15 x | 2.04 x | 5.39 x | 4.31 x | 7.83 x |
| Nbr of stocks (in thousands) | 19,431 | 42,931 | 75,944 | 91,681 | 91,981 | 104,025 |
| Reference price 2 | 28.00 | 3.600 | 2.605 | 7.890 | 4.495 | 7.100 |
| Announcement Date | 4/29/19 | 4/21/20 | 4/21/21 | 4/27/22 | 4/20/23 | 4/24/24 |
1NOK in Million2NOK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 108.4 | 84.44 | 57.79 | 50.76 | 48.29 | 34.38 |
| EBITDA 1 | -160.9 | -152.4 | -86.88 | -52.91 | -42.73 | -60.28 |
| EBIT 1 | -170.9 | -164.6 | -98.62 | -58.25 | -48.07 | -65.28 |
| Operating Margin | -157.66% | -194.92% | -170.66% | -114.77% | -99.54% | -189.85% |
| Earnings before Tax (EBT) 1 | -171.3 | -164.3 | -104.8 | -58.39 | -46.39 | -65.5 |
| Net income 1 | -172.9 | -166.4 | -101.8 | -60.01 | -46.33 | -65.73 |
| Net margin | -159.51% | -197.13% | -176.16% | -118.24% | -95.94% | -191.18% |
| EPS 2 | -9.300 | -4.024 | -1.584 | -0.6725 | -0.5048 | -0.6908 |
| Free Cash Flow 1 | -81.7 | -67.77 | -48.85 | -18.59 | -17.26 | -34.15 |
| FCF margin | -75.38% | -80.26% | -84.54% | -36.62% | -35.74% | -99.32% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 4/29/19 | 4/21/20 | 4/21/21 | 4/27/22 | 4/20/23 | 4/24/24 |
1NOK in Million2NOK
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 |
|---|---|---|---|---|---|---|
| Net sales | 12.4 | 13.7 | - | - | - | - |
| EBITDA | -13.64 | -16.17 | - | - | - | - |
| EBIT | -15.45 | -11.7 | - | - | - | - |
| Operating Margin | -124.61% | -85.42% | - | - | - | - |
| Earnings before Tax (EBT) 1 | -14.3 | -19.49 | -14.25 | -9.442 | -10.51 | -12.19 |
| Net income 1 | -15.57 | -19.81 | -14.24 | -9.527 | -10.64 | -11.93 |
| Net margin | -125.59% | -144.57% | - | - | - | - |
| EPS 2 | -0.1700 | -0.2200 | -0.1600 | -0.1000 | -0.1200 | -0.1300 |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 11/3/21 | 2/23/22 | 5/11/22 | 8/16/22 | 11/2/22 | 2/22/23 |
1NOK in Million2NOK
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 46.3 | 80.7 | 56.7 | 99.1 | 67.3 | 66.1 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -81.7 | -67.8 | -48.9 | -18.6 | -17.3 | -34.1 |
| ROE (net income / shareholders' equity) | -122% | -131% | -87.8% | -51.9% | -40.2% | -69.1% |
| ROA (Net income/ Total Assets) | -61.8% | -63.7% | -40.5% | -24.8% | -21.2% | -33.9% |
| Assets 1 | 279.6 | 261.3 | 251.3 | 241.6 | 218.6 | 193.9 |
| Book Value Per Share 2 | 6.140 | 3.140 | 1.280 | 1.460 | 1.040 | 0.9100 |
| Cash Flow per Share 2 | 2.380 | 2.060 | 0.8900 | 1.120 | 0.7500 | 0.6500 |
| Capex 1 | 0.44 | 1.2 | 0.09 | 0.2 | 0.07 | 0.01 |
| Capex / Sales | 0.4% | 1.42% | 0.15% | 0.4% | 0.14% | 0.04% |
| Announcement Date | 4/29/19 | 4/21/20 | 4/21/21 | 4/27/22 | 4/20/23 | 4/24/24 |
1NOK in Million2NOK
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +20.00% | 80.39M | |
| -25.52% | 1.55B | |
| +178.50% | 161M | |
| +14.63% | 120M | |
| -67.88% | 53.47M |
- Stock Market
- Equities
- NEXT Stock
- Financials NEXT Biometrics Group ASA
